Insights That Move the GPCR Field Forward

Drug discovery is built on a seductive simplification: identify the malfunctioning receptor, design a compound that engages it, and restore function. But many diseases don't cooperate with that assumption. Alzheimer's, metabolic disease, psychiatric pharmacology — each carries evidence of multi-receptor architecture. Multi-target GPCR pharmacology is not a workaround. In certain disease architectures, it is the pharmacologically correct approach.

GPCR biologic drugs stabilize receptor active states through distributed contact networks small molecules have trouble reproducing. The affinity-trap account, treated as a model rather than a verdict, explains a recurring difficulty at family B GPCR programs.

GPCR internalization does not end signaling — it redirects it. This article explores the assays, beta-arrestin gating mechanisms, and recycling-versus-degradation frameworks that determine receptor fate inside the cell.

Modern drug discovery produces thousands of compounds—but only pharmacology turns assay signals into predictions. Explore the drug discovery pharmacology principles guiding receptor signaling, potency interpretation, residence time, and real-world drug behavior.